• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用对接和分子动力学模拟鉴定抗病毒植物化学物质作为潜在的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶(Mpro)抑制剂

Identification of antiviral phytochemicals as a potential SARS-CoV-2 main protease (M) inhibitor using docking and molecular dynamics simulations.

作者信息

Patel Chirag N, Jani Siddhi P, Jaiswal Dharmesh G, Kumar Sivakumar Prasanth, Mangukia Naman, Parmar Robin M, Rawal Rakesh M, Pandya Himanshu A

机构信息

Department of Botany, Bioinformatics, and Climate Change Impacts Management, School of Sciences, Gujarat University, Ahmedabad, 380009, India.

BioInnovations, Bhayander (West), Mumbai, 401101, India.

出版信息

Sci Rep. 2021 Oct 13;11(1):20295. doi: 10.1038/s41598-021-99165-4.

DOI:10.1038/s41598-021-99165-4
PMID:34645849
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8514552/
Abstract

Novel SARS-CoV-2, an etiological factor of Coronavirus disease 2019 (COVID-19), poses a great challenge to the public health care system. Among other druggable targets of SARS-Cov-2, the main protease (M) is regarded as a prominent enzyme target for drug developments owing to its crucial role in virus replication and transcription. We pursued a computational investigation to identify M inhibitors from a compiled library of natural compounds with proven antiviral activities using a hierarchical workflow of molecular docking, ADMET assessment, dynamic simulations and binding free-energy calculations. Five natural compounds, Withanosides V and VI, Racemosides A and B, and Shatavarin IX, obtained better binding affinity and attained stable interactions with M key pocket residues. These intermolecular key interactions were also retained profoundly in the simulation trajectory of 100 ns time scale indicating tight receptor binding. Free energy calculations prioritized Withanosides V and VI as the top candidates that can act as effective SARS-CoV-2 M inhibitors.

摘要

新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是2019冠状病毒病(COVID-19)的病原体,给公共卫生保健系统带来了巨大挑战。在SARS-CoV-2的其他可成药靶点中,主要蛋白酶(M)因其在病毒复制和转录中的关键作用,被视为药物开发的重要酶靶点。我们进行了一项计算研究,使用分子对接、ADMET评估、动力学模拟和结合自由能计算的分层工作流程,从一个已编译的具有抗病毒活性的天然化合物库中识别M抑制剂。五种天然化合物,即睡茄苷V和VI、总状土木香苷A和B以及印度人参苷IX,获得了更好的结合亲和力,并与M关键口袋残基形成了稳定的相互作用。这些分子间的关键相互作用在100纳秒时间尺度的模拟轨迹中也得到了深刻保留,表明受体结合紧密。自由能计算将睡茄苷V和VI列为可作为有效SARS-CoV-2 M抑制剂的首选候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/a7339e847fee/41598_2021_99165_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/5be186e7b614/41598_2021_99165_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/2ae77114c684/41598_2021_99165_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/61d08605614f/41598_2021_99165_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/ed134043cb18/41598_2021_99165_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/6df3afbfc2bc/41598_2021_99165_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/3e391db17ae6/41598_2021_99165_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/447a72cc7ab6/41598_2021_99165_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/8634ef44f408/41598_2021_99165_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/a7339e847fee/41598_2021_99165_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/5be186e7b614/41598_2021_99165_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/2ae77114c684/41598_2021_99165_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/61d08605614f/41598_2021_99165_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/ed134043cb18/41598_2021_99165_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/6df3afbfc2bc/41598_2021_99165_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/3e391db17ae6/41598_2021_99165_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/447a72cc7ab6/41598_2021_99165_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/8634ef44f408/41598_2021_99165_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b87/8514552/a7339e847fee/41598_2021_99165_Fig9_HTML.jpg

相似文献

1
Identification of antiviral phytochemicals as a potential SARS-CoV-2 main protease (M) inhibitor using docking and molecular dynamics simulations.使用对接和分子动力学模拟鉴定抗病毒植物化学物质作为潜在的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶(Mpro)抑制剂
Sci Rep. 2021 Oct 13;11(1):20295. doi: 10.1038/s41598-021-99165-4.
2
Exploring epigenetic drugs as potential inhibitors of SARS-CoV-2 main protease: a docking and MD simulation study.探讨表观遗传药物作为 SARS-CoV-2 主蛋白酶潜在抑制剂的研究:对接和 MD 模拟研究。
J Biomol Struct Dyn. 2024 Aug;42(13):6892-6903. doi: 10.1080/07391102.2023.2236714. Epub 2023 Jul 17.
3
Investigation of bio-active Amaryllidaceae alkaloidal small molecules as putative SARS-CoV-2 main protease and host TMPRSS2 inhibitors: interpretation by simulation study.基于模拟研究的新型 SARS-CoV-2 主要蛋白酶和宿主 TMPRSS2 抑制剂候选物——石蒜科生物活性生物碱小分子的研究
J Biomol Struct Dyn. 2024 Sep;42(14):7107-7127. doi: 10.1080/07391102.2023.2238065. Epub 2023 Jul 24.
4
Identification of Pyrazole Derivatives of Usnic Acid as Novel Inhibitor of SARS-CoV-2 Main Protease Through Virtual Screening Approaches.通过虚拟筛选方法鉴定松萝酸的吡唑衍生物作为新型严重急性呼吸综合征冠状病毒2主蛋白酶抑制剂
Mol Biotechnol. 2024 Apr;66(4):696-706. doi: 10.1007/s12033-023-00667-5. Epub 2023 Feb 8.
5
Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.合成类黄酮作为抗 SARS-CoV-2 主蛋白酶的潜在抗病毒药物。
J Biomol Struct Dyn. 2022 May;40(8):3777-3788. doi: 10.1080/07391102.2020.1850359. Epub 2020 Nov 30.
6
Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - (Ashwagandha), (Giloy) and (Tulsi) - a molecular docking study.通过阿育吠陀药用植物( Ashwagandha )、( Giloy )和( Tulsi )的活性植物化学成分靶向 COVID-19 ( SARS-CoV-2 )主蛋白酶 - ( Ashwagandha )、( Giloy )和( Tulsi ) - 分子对接研究。
J Biomol Struct Dyn. 2022 Jan;40(1):190-203. doi: 10.1080/07391102.2020.1810778. Epub 2020 Aug 27.
7
Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.针对 SARS-CoV-2 主蛋白酶的选择性潜在抗病毒药物的分子对接、结合模式分析、分子动力学和 ADMET/毒性性质预测:药物再利用以对抗 COVID-19 的努力。
Mol Divers. 2021 Aug;25(3):1905-1927. doi: 10.1007/s11030-021-10188-5. Epub 2021 Feb 13.
8
Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.基于结构的抗 SARS-CoV-2 主蛋白酶抑制剂的抗病毒专用化学文库筛选:一种详尽的计算筛选方法。
Mol Divers. 2021 Aug;25(3):1979-1997. doi: 10.1007/s11030-021-10214-6. Epub 2021 Apr 12.
9
Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.靶向 SARS-CoV-2 主蛋白酶:一项计算药物再利用研究。
Arch Med Res. 2021 Jan;52(1):38-47. doi: 10.1016/j.arcmed.2020.09.013. Epub 2020 Sep 17.
10
In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.计算机分析与鉴定新型冠状病毒 SARS-CoV-2 的 3-糜蛋白酶样主蛋白酶的抗病毒香豆素衍生物。
Mol Divers. 2022 Apr;26(2):1053-1076. doi: 10.1007/s11030-021-10230-6. Epub 2021 Jul 2.

引用本文的文献

1
Targeting SARS-CoV-2 main protease: a pharmacophore and molecular modeling approach.靶向严重急性呼吸综合征冠状病毒2主蛋白酶:一种药效团和分子建模方法。
J Mol Model. 2025 Jul 29;31(8):222. doi: 10.1007/s00894-025-06441-5.
2
Pharmacokinetic, toxicological, and molecular interaction assessment of ginger-derived phenolics for SARS-CoV-2 main protease Inhibition.姜衍生酚类物质对新型冠状病毒主要蛋白酶抑制作用的药代动力学、毒理学及分子相互作用评估
Sci Rep. 2025 Jul 28;15(1):27390. doi: 10.1038/s41598-025-13094-0.
3
Mechanism and implications of advanced glycation end products (AGE) and its receptor RAGE axis as crucial mediators linking inflammation and obesity.

本文引用的文献

1
Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M.基于药效团的方法在FDA批准药物针对SARS-CoV-2 M的合理重新利用技术中的应用
RSC Adv. 2020 Nov 4;10(66):40264-40275. doi: 10.1039/d0ra06038k. eCollection 2020 Nov 2.
2
Structure-based virtual screening and molecular dynamics of phytochemicals derived from Saudi medicinal plants to identify potential COVID-19 therapeutics.基于结构的沙特药用植物来源植物化学物质虚拟筛选及分子动力学研究以鉴定潜在的COVID-19治疗药物。
Arab J Chem. 2020 Sep;13(9):7224-7234. doi: 10.1016/j.arabjc.2020.08.004. Epub 2020 Aug 9.
3
晚期糖基化终末产物(AGE)及其受体RAGE轴作为连接炎症和肥胖的关键介质的机制及影响
Mol Biol Rep. 2025 Jun 5;52(1):556. doi: 10.1007/s11033-025-10632-x.
4
Data on the docking of millet-derived secondary metabolites as multi-target ligands for diabetes.小米衍生的次生代谢产物作为糖尿病多靶点配体的对接数据。
Data Brief. 2025 Jan 11;59:111290. doi: 10.1016/j.dib.2025.111290. eCollection 2025 Apr.
5
Exploring the therapeutic mechanisms of millet in obesity through molecular docking, pharmacokinetics, and dynamic simulation.通过分子对接、药代动力学和动态模拟探索小米在肥胖症中的治疗机制。
Front Nutr. 2024 Oct 18;11:1453819. doi: 10.3389/fnut.2024.1453819. eCollection 2024.
6
Breaking the Chain: Protease Inhibitors as Game Changers in Respiratory Viruses Management.打破链条:蛋白酶抑制剂在呼吸道病毒管理中的变革作用。
Int J Mol Sci. 2024 Jul 25;25(15):8105. doi: 10.3390/ijms25158105.
7
Investigating the Antiviral Properties of Linn against the Ebola, SARS-CoV-2, Nipah, and Chikungunya Viruses: A Computational Simulation Study.研究Linn对埃博拉病毒、SARS-CoV-2、尼帕病毒和基孔肯雅病毒的抗病毒特性:一项计算模拟研究
Pharmaceuticals (Basel). 2024 Apr 30;17(5):581. doi: 10.3390/ph17050581.
8
Harnessing Brazilian biodiversity database: identification of flavonoids as potential inhibitors of SARS-CoV-2 main protease using computational approaches and all-atom molecular dynamics simulation.利用巴西生物多样性数据库:通过计算方法和全原子分子动力学模拟确定黄酮类化合物作为新型冠状病毒主要蛋白酶的潜在抑制剂。
Front Chem. 2024 Feb 22;12:1336001. doi: 10.3389/fchem.2024.1336001. eCollection 2024.
9
An Aedes-Anopheles Vaccine Candidate Supplemented with BCG Epitopes Against the Aedes and Anopheles Genera to Overcome Hypersensitivity to Mosquito Bites.一种含有 BCG 表位的伊蚊-按蚊疫苗候选物,可克服对蚊虫叮咬的过敏反应。
Acta Parasitol. 2024 Mar;69(1):483-504. doi: 10.1007/s11686-023-00771-1. Epub 2024 Jan 9.
10
Protective Effects of Rhamnetin in Carbapenem-Resistant -Induced Sepsis Model and the Underlying Mechanism.瑞香素对碳青霉烯类耐药诱导脓毒症模型的保护作用及作用机制。
Int J Mol Sci. 2023 Oct 26;24(21):15603. doi: 10.3390/ijms242115603.
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply.
新冠病毒疫苗对B.1.617.2(德尔塔)变异株的有效性。回复
N Engl J Med. 2021 Dec 16;385(25):e92. doi: 10.1056/NEJMc2113090. Epub 2021 Nov 10.
4
AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings.AutoDock Vina 1.2.0:新的对接方法、扩展的力场及Python绑定
J Chem Inf Model. 2021 Aug 23;61(8):3891-3898. doi: 10.1021/acs.jcim.1c00203. Epub 2021 Jul 19.
5
A critical overview of computational approaches employed for COVID-19 drug discovery.用于 COVID-19 药物发现的计算方法的批判性综述。
Chem Soc Rev. 2021 Aug 21;50(16):9121-9151. doi: 10.1039/d0cs01065k. Epub 2021 Jul 2.
6
Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening.基于配体和结构的虚拟筛选鉴定已知药物作为潜在的 SARS-CoV-2 Mpro 抑制剂。
Future Med Chem. 2021 Aug;13(16):1353-1366. doi: 10.4155/fmc-2021-0025. Epub 2021 Jun 25.
7
Identification of Severe Acute Respiratory Syndrome Coronavirus-2 inhibitors through in silico structure-based virtual screening and molecular interaction studies.通过基于结构的计算机虚拟筛选和分子相互作用研究鉴定严重急性呼吸综合征冠状病毒 2 抑制剂。
J Mol Recognit. 2021 Oct;34(10):e2918. doi: 10.1002/jmr.2918. Epub 2021 Jun 15.
8
Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2.计算机模拟确定海洋来源的天然生物活性化合物为SARS-CoV-2的复制抑制剂。
Front Microbiol. 2021 Apr 21;12:647295. doi: 10.3389/fmicb.2021.647295. eCollection 2021.
9
Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.通过对韩国化合物库进行虚拟筛选,鉴定出针对严重急性呼吸综合征冠状病毒 2 的非共价 3CL 样蛋白酶抑制剂。
Bioorg Med Chem Lett. 2021 Jun 15;42:128067. doi: 10.1016/j.bmcl.2021.128067. Epub 2021 May 3.
10
The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)毒株的出现。这对2019冠状病毒病(COVID-19)疫苗意味着什么?
Expert Rev Vaccines. 2021 Jun;20(6):635-638. doi: 10.1080/14760584.2021.1915140. Epub 2021 Apr 25.